SCHEMBL20564951

SCHEMBL20564951

CC(C)c1c(O)nc(-n2ccnc2)nc1OCC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 7/20 0.40
CYP3A4 P08684 3/20 0.39
CYP26A1 O43174 2/20 0.39
TBXAS1 P24557 7/20 0.39
TSHR P16473 3/20 0.35
NPC1 O15118 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 2/20 0.34
MAPK1 P28482 2/20 0.34
CYP2B6 P20813 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ATM Q13315 1/20 0.34
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20958060 0.89 CD38 (0.41) CD38CYP3A4CYP26A1TSHRNPC1
SCHEMBL20980441 0.85 CD38 (0.38) CD38CYP3A4LMNANPSR1CYP2D6
SCHEMBL20563854 0.84 CD38 (0.38) CD38CYP3A4LMNANPSR1CYP2D6
SCHEMBL20565316 0.83 ALDH1A1 (0.37) CD38TSHRNPC1HSD17B10TDP1
SCHEMBL20958063 0.83 TSHR (0.42) CYP3A4CYP26A1TBXAS1TSHRNPC1
SCHEMBL20958012 0.82 FKBP1A (0.44) CD38TSHRNPC1MEN1USP2
SCHEMBL20957951 0.81 CYP3A4 (0.46) CD38CYP3A4TBXAS1TSHRKMT2A
SCHEMBL20564999 0.81 TSHR (0.39) CD38CYP3A4TBXAS1TSHRNPC1
SCHEMBL20564651 0.81 CYP26A1 (0.47) CYP3A4CYP26A1TBXAS1KDM4E
SCHEMBL20957980 0.81 CYP1A2 (0.47) CD38CYP3A4TSHRNPC1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
WO-2018213777-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE KDM5A, KDM5B, KDM5C CD38 791/4885CYP3A4 3097/4885CYP26A1 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.